Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions for Blisibimod

Anthera Pharmaceuticals, Inc.

today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States. Anthera does not intend to communicate further regarding these discussions unless and until a definitive agreement is executed. There can be no assurance that such a definitive agreement will be executed relating to any proposed partnership, or that any partnership will be approved or consummated. "While we cannot be certain of the eventual outcome of our strategic discussions, our negotiations have reached a point where we believe it is important to hold off on further updates regarding the blisibimod clinical program," commented Paul F. Truex, President and CEO of Anthera. "We will provide further information regarding the status of the blisibimod clinical program upon completion of these negotiations."